Aton Ra Partners Seagen Inc. Transaction History

Aton Ra Partners

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 02, 2023	SELL	$117.37 - $139.17 $170,890 - $202,631	-1,456 Reduced 26.85%	3,967 $509,000
Q3 2022 Nov 14, 2022	BUY	$135.27 - $180.11 $11,768 - $15,669	87 Added 1.63%	5,423 $742,000
Q2 2022 Aug 15, 2022	SELL	$108.81 - $179.33 $189,329 - $312,034	-1,740 Reduced 24.59%	5,336 $944,000
Q1 2022 May 16, 2022	SELL	$119.61 - $157.85 $225,584 - $297,705	-1,886 Reduced 21.04%	7,076 $1.02 Million
Q4 2021 Feb 14, 2022	BUY	$142.57 - $190.86 $136,867 - $183,225	960 Added 12.0%	8,962 $1.39 Million

Q3 2021 Nov 15, 2021	BUY	$142.45 - $169.82 $104,273 - $124,308	732 Added 10.07%	8,002 $1.36 Million
Q2 2021 Aug 12, 2021	BUY	$135.08 - $161.1 $109,684 - $130,813	812 Added 12.57%	7,270 $1.15 Million
Q1 2021 May 17, 2021	BUY	$137.51 - $190.8 $157,586 - $218,656	1,146 Added 21.57%	6,458 $897,000
Q4 2020 Feb 19, 2021	BUY	$164.63 - $211.93 $874,514 - $1.13 Million	5,312 New	5,312 $930,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Aton Ra Partners, based on Form 13F filings with the SEC.

Stay updated on Aton Ra Partners with notifications on news.